Thermo Fisher Scientific filings document operating results, material agreements, governance matters and capital-structure disclosures for a global supplier of scientific instruments, laboratory products, diagnostics, life science tools and pharmaceutical services. Recent Form 8-K reports include quarterly and annual results, acquisition-related events and definitive agreements.
The company’s proxy materials cover shareholder voting and board-governance matters. Its securities disclosures identify common stock and multiple NYSE-listed senior note classes, while Form 25 filings document removal from listing and registration for specific senior notes. The filing record also includes risk-factor and corporate disclosure categories tied to Thermo Fisher’s operating businesses and financing structure.
Thermo Fisher Scientific Chairman & CEO Marc N. Casper reported two tax-withholding dispositions of common stock on February 28, 2026. He delivered 3,473.759 shares and 1,211.168 shares at $521.11 per share to cover tax liabilities, rather than executing open-market sales. Following these dispositions, he directly held 123,925.358 common shares. Additional common shares are held indirectly by the Alison Casper 2020 Irrevocable Trust, the MNC 2020 Irrevocable Trust, and Floral Park Associates, Inc., for which he disclaims beneficial ownership except to any pecuniary interest.
Thermo Fisher Scientific senior vice president and chief HR officer Lisa P. Britt reported two tax-withholding share dispositions. She transferred 262.6700 and 85.4090 shares of common stock at $521.1100 per share to cover tax liabilities. After these transactions, she directly owned 14,784.1480 common shares.
Thermo Fisher Scientific executive Joseph R. Holmes, VP & Chief Accounting Officer, reported several small dispositions of common stock on February 28, 2026. The transactions used code F, meaning shares were withheld to cover tax liabilities rather than sold in open-market trades. Blocks of stock were withheld at $521.11 per share, including 55.475 and 44.459 shares. After these tax-withholding dispositions, Holmes directly held about 2,966.3555 shares of Thermo Fisher common stock.
Thermo Fisher Scientific Executive Vice President Michel Lagarde reported two tax-withholding dispositions of common stock. On February 28, 2026, he delivered 836.8800 shares and 359.7250 shares of Thermo Fisher common stock at $521.1100 per share to cover tax obligations.
Thermo Fisher Scientific President & COO Gianluca Pettiti reported two tax-withholding dispositions of common stock under a Form 4. On February 28, 2026, he surrendered 741.7100 and 331.6810 shares at $521.11 per share to cover tax obligations, and directly owned 25,450.8320 shares afterward.
Thermo Fisher Scientific executive Stephen Williamson reported tax-related share dispositions. On February 28, 2026, he used two blocks of Common Stock, totaling 921.793 shares (674.724 and 247.069 shares), to satisfy tax obligations at a price of $521.11 per share, classified as tax-withholding dispositions rather than open-market sales.
After these transactions, Williamson held 32,499.4000 shares of Common Stock directly. He also reported 12,674.0000 shares held indirectly "By SLAT," with a footnote stating he disclaims beneficial ownership of indirectly owned securities except to the extent of any pecuniary interest.
Thermo Fisher Scientific Executive Vice President Michael D. Shafer reported three Form 4 transactions on common stock. He disposed of approximately 816 shares through tax-withholding dispositions at a reported price of $521.11 per share to satisfy tax obligations. After these transactions, he directly owns about 22,557 shares of Thermo Fisher Scientific common stock.
Thermo Fisher Scientific Executive Vice President Frederick M. Lowery reported several Form 4 transactions in common stock dated February 28, 2026. He disposed of shares through tax-withholding transactions at $521.11 per share, a method used to cover tax liabilities on equity awards rather than open-market selling. Following these dispositions, he directly held 15,308.3954 shares of common stock. The filing also shows indirect holdings of common stock through a 401(k) plan and a limited liability company. A footnote states he acquired 0.037 shares under the 401(k) plan between February 26 and February 28, 2026, and that he disclaims beneficial ownership of indirectly held securities except for any pecuniary interest.
Thermo Fisher Scientific senior vice president and CFO Stephen Williamson reported an acquisition of 1,534 shares of common stock linked to a performance-based restricted stock unit award granted on February 19, 2025. On February 25, 2026, the Compensation Committee certified that the required performance goals were met.
Following this award, Williamson directly owns 33,421.193 shares of common stock. The filing also notes an indirect holding of 12,674 shares held "By SLAT," for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
Thermo Fisher Scientific Executive Vice President & COO Michel Lagarde acquired 2,231 shares of common stock through a performance-based restricted stock unit award. The award was originally granted on February 19, 2025, and the Compensation Committee certified achievement of the performance criteria on February 25, 2026.
The award vests in three equal tranches on February 28, 2026, 2027 and 2028, subject to the terms of the award agreement. Following this grant, Lagarde directly owns 86,347.909 shares of Thermo Fisher Scientific common stock.